Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

OBJECTIVES: Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase 3 trials designed to evaluate efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Deodhar, Atul, Baraliakos, Xenofon, Brown, Matthew A, Dobashi, Hiroaki, Dougados, Maxime, Elewaut, Dirk, Ellis, Alicia M, Fleurinck, Carmen, Gaffney, Karl, Gensler, Lianne S, Haroon, Nigil, Magrey, Marina, Maksymowych, Walter P, Marten, Alexander, Massow, Ute, Oortgiesen, Marga, Poddubnyy, Denis, Rudwaleit, Martin, Shepherd-Smith, Julie, Tomita, Tetsuya, Van den Bosch, Filip, Vaux, Thomas, Xu, Huji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086273/
https://www.ncbi.nlm.nih.gov/pubmed/36649967
http://dx.doi.org/10.1136/ard-2022-223595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086273/
https://www.ncbi.nlm.nih.gov/pubmed/36649967
http://dx.doi.org/10.1136/ard-2022-223595

Ejemplares similares